Mogamulizumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MOGAMULIZUMAB |
|---|---|
| Type | Drug |
| Aliases | PoteligeoМогамулізумаб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ATLL DIS-MF-SEZARY |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Defucosylated humanized anti-CCR4 monoclonal antibody (enhanced ADCC) |
|---|---|
| Mechanism | Defucosylated IgG1 against CCR4 — receptor expressed on Th2 / Treg cells and on malignant T-cells in MF/Sézary, ATLL. Defucosylation enhances ADCC ~100-fold via FcγRIIIa engagement → potent depletion of CCR4+ cells. Highest activity in Sézary syndrome (blood compartment) where CCR4 expression is most uniform. |
| Typical dosing | MF/Sézary: 1.0 mg/kg IV over ≥1 hour weekly × 5 (induction), then every 2 weeks until progression or unacceptable toxicity. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Severe skin reactions (including SJS/TEN)
- Increased risk of Grade 3-4 GVHD if allo-SCT planned downstream — discuss with transplant team
Notes
MAVORIC trial (Kim 2018): mogamulizumab vs vorinostat in r/r MF/Sézary — superior PFS especially in Sézary syndrome (blood compartment response). 1L use in advanced MF/Sézary emerging (NCCN). Ukraine: NOT registered → import-only with МОЗ exception or clinical-trial enrollment. Mandatory dermatology partnership for skin AE management.
Used By
Indications
IND-ATLL-1L-AGGRESSIVE- IND-ATLL-1L-AGGRESSIVE
Regimens
REG-MOGAMULIZUMAB- Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks)